ATE228367T1 - Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein - Google Patents

Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein

Info

Publication number
ATE228367T1
ATE228367T1 AT99926749T AT99926749T ATE228367T1 AT E228367 T1 ATE228367 T1 AT E228367T1 AT 99926749 T AT99926749 T AT 99926749T AT 99926749 T AT99926749 T AT 99926749T AT E228367 T1 ATE228367 T1 AT E228367T1
Authority
AT
Austria
Prior art keywords
genistein
carnitine
osteoporosis
prophylaxis
treatment
Prior art date
Application number
AT99926749T
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Application granted granted Critical
Publication of ATE228367T1 publication Critical patent/ATE228367T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT99926749T 1998-06-23 1999-06-17 Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein ATE228367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
PCT/IT1999/000174 WO1999066913A2 (en) 1998-06-23 1999-06-17 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein

Publications (1)

Publication Number Publication Date
ATE228367T1 true ATE228367T1 (de) 2002-12-15

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926749T ATE228367T1 (de) 1998-06-23 1999-06-17 Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l- carnitin und genistein

Country Status (27)

Country Link
US (1) US6335038B1 (de)
EP (1) EP1089742B1 (de)
JP (1) JP4430233B2 (de)
KR (1) KR20010071541A (de)
CN (1) CN1306434A (de)
AR (1) AR018924A1 (de)
AT (1) ATE228367T1 (de)
AU (1) AU755272B2 (de)
BR (1) BR9911440A (de)
CA (1) CA2334875C (de)
DE (1) DE69904172T2 (de)
DK (1) DK1089742T3 (de)
EE (1) EE200000741A (de)
ES (1) ES2188177T3 (de)
HU (1) HU224957B1 (de)
IL (1) IL140163A0 (de)
IS (1) IS5764A (de)
IT (1) IT1299191B1 (de)
MA (1) MA26655A1 (de)
NO (1) NO20006431L (de)
NZ (1) NZ508877A (de)
PL (1) PL192118B1 (de)
PT (1) PT1089742E (de)
SK (1) SK19292000A3 (de)
TN (1) TNSN99132A1 (de)
TR (1) TR200003735T2 (de)
WO (1) WO1999066913A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) * 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US20010039296A1 (en) * 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
IT1317079B1 (it) * 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
CN1638650A (zh) * 2001-03-09 2005-07-13 雀巢制品公司 改善与年龄有关的生理缺陷并延长寿命的组合物
MXPA03008137A (es) * 2001-03-15 2003-12-12 Roche Vitamins Ag Composicion para prevencion de osteoporosis que comprende combinacion de isoflavonas y acidos grasos poliinsaturados.
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
JP2005524638A (ja) * 2002-02-15 2005-08-18 エヌ・ヴイ・ヌートリシア 骨粗しょう症及び肥満処置用医薬の製造におけるゲニステインの使用及びビタミンｄ及びｋと組合わせてゲニステインを含有する組成物
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
PT1581199E (pt) * 2002-09-09 2015-04-27 Nestec Sa Composição oralmente adiminstrável para melhorar a qualidade da pele
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
US7582674B2 (en) * 2003-05-27 2009-09-01 Dsm Ip Assets B.V. Nutraceutical compositions and use thereof
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
EP1711070B1 (de) * 2004-01-28 2015-12-09 Nestec S.A. Nährzusammensetzung zur verbesserung des hautzustandes und zur vorbeugung gegen hautkrankheiten
WO2005074905A1 (ja) 2004-02-03 2005-08-18 Kotosugi Inc. 雲南紅豆杉由来イソタキシレシノールを成分とする骨粗しょう症治療・予防薬
EP2208422B1 (de) * 2004-03-17 2015-11-25 Nestec S.A. Zubereitungen und Verfahren zur Minderung oder Prävention von Adiposität
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
WO2006071919A2 (en) 2004-12-29 2006-07-06 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
CA2593335A1 (en) * 2005-01-10 2006-07-13 Hormos Medical Ltd. The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
RS52735B (sr) * 2005-07-08 2013-08-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena kombinacije koja sadrži l-karnitin ili alkanoil l-karnitin, benzokvinon rastvorljiv u mastima i omega-3-polinezasićenu masnu kiselinu za pripremu dodataka ishrani ili leka za lečenje oboljenja rožnjače
EP1906912B1 (de) 2005-07-14 2012-08-15 Hill's Pet Nutrition, Inc. Verfahren zur verlängerung des lebens von tieren
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
KR20080068850A (ko) * 2005-10-14 2008-07-24 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도
US8226973B2 (en) * 2005-11-02 2012-07-24 Nestec, S. A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
JP5227195B2 (ja) 2006-02-28 2013-07-03 ネステク ソシエテ アノニム 骨成長の誘発及び骨損失の抑制のための組成物及び方法
US20090221690A1 (en) 2006-02-28 2009-09-03 Council Of Scientific And Industrial Research Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof
EP2004161B8 (de) * 2006-04-12 2013-04-17 Unilever PLC Orale zusammensetzung mit dha und genistein zur verbesserung der hauteigenschaften
PL2189155T3 (pl) * 2006-04-12 2016-07-29 Unilever Nv Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
ES2391305T3 (es) * 2006-04-12 2012-11-23 Unilever N.V. Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
WO2008100560A2 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
AU2009292555B2 (en) 2008-09-10 2014-05-29 AGC Inc. Novel prostaglandin I2 derivative
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
BRPI0921679A2 (pt) * 2008-11-11 2016-02-16 Sigma Tau Ind Farmaceuti composto útil para tratar celulite
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
RU2564414C2 (ru) * 2010-03-08 2015-09-27 Какен Фармасьютикал Ко., Лтд. Новый агонист ер4
PT2582368T (pt) * 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
WO2012011572A1 (ja) * 2010-07-23 2012-01-26 国立大学法人大阪大学 拡張不全型心不全治療薬
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases

Also Published As

Publication number Publication date
IS5764A (is) 2000-12-08
NO20006431L (no) 2001-02-22
DK1089742T3 (da) 2003-03-24
PL192118B1 (pl) 2006-09-29
DE69904172D1 (de) 2003-01-09
TR200003735T2 (tr) 2001-03-21
AU755272B2 (en) 2002-12-05
AR018924A1 (es) 2001-12-12
NO20006431D0 (no) 2000-12-15
JP4430233B2 (ja) 2010-03-10
EP1089742A2 (de) 2001-04-11
ES2188177T3 (es) 2003-06-16
MA26655A1 (fr) 2004-12-20
EE200000741A (et) 2002-04-15
WO1999066913A3 (en) 2000-04-20
KR20010071541A (ko) 2001-07-28
JP2002518437A (ja) 2002-06-25
PL345030A1 (en) 2001-11-19
HUP0102879A3 (en) 2002-12-28
IT1299191B1 (it) 2000-02-29
NZ508877A (en) 2002-09-27
CA2334875A1 (en) 1999-12-29
WO1999066913A2 (en) 1999-12-29
TNSN99132A1 (fr) 2005-11-10
ITRM980417A1 (it) 1999-12-23
HU224957B1 (en) 2006-04-28
AU4390999A (en) 2000-01-10
DE69904172T2 (de) 2003-08-28
IL140163A0 (en) 2002-02-10
BR9911440A (pt) 2001-03-20
CN1306434A (zh) 2001-08-01
HUP0102879A2 (hu) 2002-03-28
CA2334875C (en) 2009-05-12
US6335038B1 (en) 2002-01-01
ITRM980417A0 (it) 1998-06-23
EP1089742B1 (de) 2002-11-27
SK19292000A3 (sk) 2001-08-06
PT1089742E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
DE69904172D1 (de) Zusammensetzung zur prophylaxe und/oder behandlung von osteoporosis und änderungen durch menopausal-syndrom, enthaltend propionyl-l-carnitin und genistein
DE69822822D1 (de) Verwendung einer Zusammensetzung enthaltend Capsaicin oder Resiniferatoxin zur Behandlung des Reizdarmsyndroms
DE69822919D1 (de) Spezifische Antikörper zur Verwendung in der Herstellung pharmazeutischer Zusammensetzungen nützlich für die Vorbeugung oder Behandlung von Gastritis, Magen- und Zwölffingerdarmgeschwüren
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE279407T1 (de) Fsh mimetika zur behandlung von infertilität
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE240107T1 (de) Neue verbesserte formulierung zur behandlung der osteoporose
ATE228369T1 (de) Nervenschützende zusammensetzung zur prophylaxe und behandlung von nervös- und verhaltungsänderungen durch angstartigen zuständen oder depressionen, die acetyl-l- carnitin und hypericin enthalt
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
DE69941821D1 (de) Fluorenthaltende zusammensetzung zur behandlung von oberflächen
ATE230597T1 (de) Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen
DE60100930D1 (de) Resistzusammensetzung und Verfahren zur Herstellung von Halbleiterbauelementen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
HUP0302309A3 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity and for preparation of pharmaceutical compositions containing them
DE69902127D1 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60018591D1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1089742

Country of ref document: EP